Vimta Labs

Who are the top shareholders of the Vimta Labs?

The top shareholders of Vimta Labs include Eurofins Analytical Services India Pvt Ltd with 19.81%, individual investors with 25.17%, and promoter Sivalinga Prasad Vasireddi holding 11.69%. Additionally, 30 foreign institutional investors hold a combined 3.66%, while mutual funds have a negligible stake of 0.0%.

The top shareholders of Vimta Labs include several key players. The largest public shareholder is Eurofins Analytical Services India Pvt Ltd, holding 19.81%. Among individual investors, they collectively own 25.17%. On the promoter side, Sivalinga Prasad Vasireddi has the highest individual holding at 11.69%. Additionally, the company has 30 foreign institutional investors (FIIs) with a combined holding of 3.66%. There are also two mutual fund schemes that hold shares, but their combined stake is negligible at 0.0%.

What does Vimta Labs do?

Vimta Labs Ltd. is a leading contract research and testing organization in India, established in 1984, with a market cap of Rs 2,103 Cr and reported net sales of 94 Cr and net profit of 18 Cr for March 2025. Key metrics include a P/E of 35.00 and a return on equity of 17.82%.

Overview:<BR>Vimta Labs Ltd. is India's most comprehensive contract research and testing organization, operating in the Healthcare Services industry within the Small Cap market-cap bracket.<BR><BR>History:<BR>Vimta Labs Ltd. was established in 1984. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 94 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 18 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 2,103 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Industry P/E: 53 <BR>Dividend Yield: 0.42% <BR>Debt-Equity: -0.05 <BR>Return on Equity: 17.82% <BR>Price to Book: 6.24 <BR><BR>Contact Details:<BR>Address: Plot No 141/2 & 142, IDA Phase II Cherlapally Hyderabad Telangana : 500051 <BR>Tel: 91-40-27264141 <BR>Email: shares@vimta.com <BR>Website: http://www.vimta.com

Has Vimta Labs declared dividend?

Yes, Vimta Labs Ltd has declared a 100% dividend, amounting to ₹2 per share, with an ex-date of May 30, 2025. The company has shown strong total returns over various periods, particularly in price appreciation.

Vimta Labs Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 2 per share<BR>- Ex-date: May 30, 2025<BR><BR>Dividend Yield: 0.42%.<BR><BR>Total Returns by Period:<BR>Over the 6-month period, the price return was 1.55%, the dividend return was 0.22%, resulting in a total return of 1.77%.<BR><BR>In the 1-year period, the price return was 96.22%, with a dividend return of 0.81%, leading to a total return of 97.03%.<BR><BR>For the 2-year period, the price return was 131.01%, the dividend return was 1.47%, culminating in a total return of 132.48%.<BR><BR>During the 3-year period, the price return stood at 182.98%, the dividend return was 1.88%, which resulted in a total return of 184.86%.<BR><BR>In the 4-year period, the price return was 289.22%, with a dividend return of 3.19%, achieving a total return of 292.41%.<BR><BR>Over the 5-year period, the price return reached 1062.16%, the dividend return was 11.74%, resulting in a total return of 1073.9%.<BR><BR>Overall, Vimta Labs has declared a significant dividend, and the total returns over various periods indicate strong performance, particularly in price appreciation, suggesting a positive outlook for investors.

Who are the peers of the Vimta Labs?

Vimta Labs' peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Laxmi Dental, Krsnaa Diagnost., Tarsons Products, Suraksha Diagno., and 3B Blackbio. Vimta Labs has an average management risk, good growth rating, and the highest 1-year return among peers at 105.18%.

Peers: The peers of Vimta Labs are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Laxmi Dental, Krsnaa Diagnost., Tarsons Products, Suraksha Diagno., and 3B Blackbio.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Tarsons Products, and Average management risk is noted at Vimta Labs, Krsnaa Diagnost., and Suraksha Diagno. Growth is rated as Excellent for 3B Blackbio, Good for Vimta Labs and Laxmi Dental, Average for Poly Medicure and Indegene, and Below Average for Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., and Krsnaa Diagnost. Capital Structure is Excellent for Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and Krsnaa Diagnost., Good for Laxmi Dental and Suraksha Diagno., and Average for Vimta Labs and Tarsons Products.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vimta Labs at 105.18%, while the peer with the lowest is Tarsons Products at -6.12%. Vimta Labs' 1-year return significantly outperforms all peers. Additionally, Krsnaa Diagnost. and Tarsons Products have negative six-month returns.

What is the bonus history of the Vimta Labs?

Vimta Labs recently announced a 1:1 bonus issue, with an ex-date of June 13, 2025. Shareholders on record as of this date will receive one additional share for each share they own.

Vimta Labs has a recent bonus issue where they announced a 1:1 bonus. The ex-date for this bonus is June 13, 2025, which means that shareholders on record as of this date will receive one additional share for every share they own. This is the latest information regarding their bonus history. If you have any more questions about Vimta Labs or need further details, feel free to ask!

Who are in the management team of Vimta Labs?

As of March 2023, the management team of Vimta Labs includes S P Vasireddi (Executive Chairman), Harita Vasireddi (Managing Director), and several non-executive directors, contributing to the company's governance and operations.

As of March 2023, the management team of Vimta Labs includes:<BR><BR>1. S P Vasireddi - Executive Chairman<BR>2. V Harriman - Director (Operation)<BR>3. Harita Vasireddi - Managing Director<BR>4. Y Prameela Rani - Non-Executive & Independent Director<BR>5. Sujani Vasireddi - Company Secretary & Compliance Officer<BR>6. G Purnachandra Rao - Non-Executive & Independent Director<BR>7. Sanjay Dave - Non-Executive & Independent Director<BR>8. Satya Sreenivas Neerukonda - Executive Director<BR>9. Yadagiri R Pendri - Non-Executive & Independent Director<BR><BR>This team comprises a mix of executive and non-executive members, contributing to the governance and operational management of the company.

How big is Vimta Labs?

As of 24th July, Vimta Labs Ltd has a market capitalization of 2,304.00 Cr, with recent Net Sales of 329.23 Cr and a Net Profit of 61.38 Cr. Shareholder's Funds are 319.70 Cr and Total Assets are valued at 392.25 Cr as of March 2024.

As of 24th July, Vimta Labs Ltd has a market capitalization of 2,304.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Vimta Labs reported Net Sales of 329.23 Cr and a Net Profit of 61.38 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 319.70 Cr and Total Assets valued at 392.25 Cr.

Is Vimta Labs overvalued or undervalued?

As of July 28, 2025, Vimta Labs is considered very expensive with a PE ratio of 47.77 and other high valuation metrics, indicating it is overvalued despite a favorable PEG ratio of 0.84 and strong past performance.

As of 28 July 2025, the valuation grade for Vimta Labs has moved from expensive to very expensive. Based on the analysis, the company appears to be overvalued. The PE ratio stands at 47.77, the Price to Book Value is 8.51, and the EV to EBITDA ratio is 25.60, all indicating a premium valuation relative to its peers.<BR><BR>In comparison to its industry peers, Vimta Labs' PE ratio is lower than that of Poly Medicure, which has a PE of 58.98, but higher than Blue Jet Health at 38.38. Notably, Vimta's PEG ratio of 0.84 suggests a more favorable growth expectation relative to its price, yet the overall high valuation metrics indicate that the stock is trading at a significant premium. Furthermore, Vimta Labs has outperformed the Sensex over various time frames, including a 137.30% return over the past year, which reinforces the perception of overvaluation given the current high price levels.

Is Vimta Labs technically bullish or bearish?

As of October 10, 2025, Vimta Labs shows a mildly bullish trend supported by bullish MACD and Bollinger Bands, but tempered by a mildly bearish Dow Theory signal and a lack of momentum confirmation from the RSI.

As of 10 October 2025, the technical trend for Vimta Labs has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on both weekly and monthly time frames, and mildly bullish Bollinger Bands on the weekly chart. The daily moving averages also indicate a mildly bullish trend. However, the Dow Theory shows a mildly bearish signal on the weekly time frame, which tempers the overall bullish outlook. The RSI indicates no signal on both weekly and monthly time frames, suggesting a lack of momentum confirmation. Overall, the strength of the bullish stance is moderate, with some caution due to the mixed signals from Dow Theory and the RSI.

How has been the historical performance of Vimta Labs?

Vimta Labs' historical performance shows mixed results, with net sales decreasing to 288.60 Cr in March 2024 from 318.19 Cr in March 2023, while profit after tax increased to 48.81 Cr. Total assets rose to 392.25 Cr, but cash flow from operating activities fell to 60.00 Cr, resulting in a net cash outflow of 17.00 Cr.

Answer:<BR>The historical performance of Vimta Labs shows a mixed trend in its financial metrics over the past five years.<BR><BR>Breakdown:<BR>Vimta Labs reported net sales of 288.60 Cr in March 2024, a decrease from 318.19 Cr in March 2023, but an increase from 278.28 Cr in March 2022. The total operating income followed a similar pattern, with 288.60 Cr in March 2024 compared to 318.19 Cr in the previous year. The total expenditure, excluding depreciation, decreased to 194.56 Cr in March 2024 from 223.28 Cr in March 2023. Operating profit (PBDIT) slightly declined to 97.75 Cr in March 2024 from 98.35 Cr in March 2023, while profit before tax decreased to 62.50 Cr from 65.00 Cr in the same period. However, profit after tax increased to 48.81 Cr in March 2024 from 48.17 Cr in March 2023. The earnings per share (EPS) fell to 18.51 in March 2024 from 21.75 in March 2023, reflecting a decrease in profitability per share. On the balance sheet, total assets rose to 392.25 Cr in March 2024 from 358.01 Cr in March 2023, while total liabilities also increased to 392.25 Cr from 358.01 Cr. The cash flow from operating activities decreased to 60.00 Cr in March 2024 from 87.00 Cr in March 2023, contributing to a net cash outflow of 17.00 Cr in March 2024, compared to a net inflow of 19.00 Cr in March 2023.

Are Vimta Labs Ltd latest results good or bad?

Vimta Labs Ltd's latest Q3 FY26 results are strong, with a net profit of ₹21.50 crores, a 112.24% year-on-year increase, and revenue growth of 20.57% to ₹89.92 crores. The operating margin improved to 36.79%, indicating effective cost management and operational efficiency.

Vimta Labs Ltd's latest results for Q3 FY26 can be considered quite good overall. The company reported a consolidated net profit of ₹21.50 crores, which represents a remarkable 112.24% increase year-on-year. This significant growth in profit outpaced the revenue growth, which was at ₹89.92 crores, reflecting a 20.57% increase compared to the same quarter last year.<BR><BR>Additionally, the operating margin improved to 36.79%, marking a substantial rise of 479 basis points year-on-year. This indicates that Vimta Labs is effectively managing its costs while scaling its operations, which is a positive sign for operational efficiency.<BR><BR>The company also demonstrated strong performance in terms of return on equity, standing at 17.82%, which is indicative of effective capital utilization. Overall, the results showcase Vimta Labs' ability to grow profits significantly while maintaining healthy margins, positioning the company favorably in the competitive testing services market.

When is the next results date for Vimta Labs Ltd?

The next results date for Vimta Labs Ltd is 06 May 2026.

The next results date for Vimta Labs Ltd is scheduled for 06 May 2026.

Why is Vimta Labs Ltd falling/rising?

As of 05-May, Vimta Labs Ltd's stock price is rising to 494.35, up 3.7%, driven by strong recent performance and increased investor interest. The stock is trading above key moving averages, indicating a positive short-term trend, despite some concerns regarding its EPS and Price to Book Value ratio.

As of 05-May, Vimta Labs Ltd's stock price is rising, currently at 494.35, reflecting an increase of 17.65 or 3.7%. This upward movement can be attributed to several factors. The stock has shown strong performance over the past week, gaining 9.08%, and has risen 10.61% over the last three days. Additionally, the stock's performance today is in line with the sector, which has seen a gain of 4.49% in the Medical Equipment/Supplies/Accessories category.<BR><BR>Investor participation has also increased, with a delivery volume of 1.2 lacs on 04 May, which is a significant rise of 79.95% compared to the five-day average. This indicates growing interest and confidence among investors. Furthermore, the stock is currently trading above its 5-day, 20-day, and 50-day moving averages, suggesting a positive short-term trend, even though it remains below the 100-day and 200-day moving averages.<BR><BR>Despite some negative factors, such as a flat EPS result and a relatively high Price to Book Value ratio, the company has demonstrated healthy long-term growth with an operating profit growth rate of 38.59% annually. This growth, combined with a low Debt to Equity ratio of 0.03 times, contributes to a favorable outlook for the stock, supporting its recent price rise.

Which are the latest news on Vimta Labs?

Should I buy, sell or hold Vimta Labs Ltd?